T2 Biosystems Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
T2 Biosystems (TTOO) Reports Q4 Revenues Below Estimates; Provides Q1 & FY19 Revenue Outlook
March 7, 2019 4:42 PM ESTT2 Biosystems (NASDAQ: TTOO) reported Q4 EPS of $. Revenue for the quarter came in at $1.8 million versus the consensus estimate of $2.67 million.
Reported fourth quarter total revenue of $1.8 million, up 6% year-over-year.Reported fourth quarter product revenue of $1.3 million reflecting increased testing volume and stable capital sales as more new customers selected the reagent rental model.Secured a record 14 new contracts of T2Dx® Instruments in the fourth quarter, which was at the high end of 2H18 guidance.Increased targeted high-risk patients at newly contracted hospitals by over... More